Remiges Ventures, Inc. — Full Portfolio
26 tracked investments · listed companies and verified rows first
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)Kenneth Horne(Executive Officer, Director)inDylan Morris(Director)Cristina Ghenoiu(Director)
BoardTaro Inaba(Director)inKen Horne
Co-investorsInsight PartnersRA CapitalAN Venture PartnersRDiscovery
Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.
BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US
Rick Geoffrion(Founder, President and CEO & Board Member)
Co-investorsDeepWork CapitalLumira Ventures
Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases.
AI & Machine LearningBiotechMedical DevicesSchönefeld, DE
Johanna Holldack(CEO)
BoardPierre Morgon(Chairman)Wolfram Nothaft(Deputy Chairman)
Co-investorsBrandenburg KapitalVentura BioMed Investors
Myrodia Therapeutics is a Japanese biopharmaceutical company developing drug candidates based on its "sensory drug discovery" concept, which uses sensory stimuli to induce artificial hibernation and protective physiological states.
BiotechDeep TechHealthtech
小早川 高(CSO / Founder)小早川 令子(Founder)神谷 勇輝(CEO / 代表取締役)水野 敦之(CFO)小林 実(COO)
Co-investorsANRIRDiscovery
OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.
BiotechHealthtechBerlin, DE
Robert Fischer(CEO/CSO & Co-Founder)Karen Uhlmann(Vice President Operations & IP, Co-Founder)Wolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)
Co-investorsForbionVesalius Biocapital Partners
Clinical-stage biopharmaceutical company developing oligonucleotide therapeutics using an immune cell-targeted delivery platform.
BiotechBurlingame, US
BoardWalter Olesiak(Executive Officer, Director)Taro Inaba(Director)
Board seatKazuhiko Nonomura· per SEC Form D · $2M raise · filed Sep 2021
Co-investorsMitsui Global Investment
Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
HealthtechWashington, US
Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)
BoardGerry Brunk(Director)inTakahide Koda(Director)
Co-investorsDeepWork CapitalLumira Ventures
ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation.
BiotechHealthtechNew York, US
Sumayah Jamal(President, Co-founder & Chief Scientific Officer)Robert Schneider(Co-founder & Chair of Scientific Advisory Board)Sandy Harm(Chief Operating Officer)Fumitaka Mori(Director)Albert Sokol(Executive Officer)
BoardBarbara Schilberg(Director)
Co-investorsBioAdvance
Endurance Bio develops first-in-class small molecules (T-168 and T-621) that target mitochondria and lysosomes to reduce oxidative stress and inflammation and enhance autophagy, aimed at treating neurodegenerative, metabolic, muscle, and aging-related diseases.
BiotechHealthtechLongevity
Frederic Godderis(Founder, CEO & Director)inEnchi Liu(Co-founder & Chief Development Officer)inAndrew Lam(Co-founder & Chief Technology Officer)inEdgar Engleman(Scientific Founder)Subhasis Roy(Chief Financial Officer & Business Development)in
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
BiotechSan Francisco, US
Christopher Starr(Director)Peter C.M. McWilliams(Director)Agnes Rafalko(Executive Officer, Director)
BoardGiacomo Chiesi(Director)
Co-investorsAdvent Life SciencesChiesi VenturesCTI Life Sciences Fund L.P.RiverVest Venture PartnersSanderling VenturesSanofi Ventures
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)
Co-investorsAdvent Life SciencesMission Bay CapitalMission BiocapitalRiverVest Venture PartnersSanderling VenturesSanofi Ventures
BiotechLaguna Beach, US
Hans Keirstead(Executive Officer, Director)Gabriel Nistor(Executive Officer)
BoardTakahide Koda(Director)Daniel Kraft(Director)
Developing secretome-based biologics; licensed a treatment candidate for Parkinson's-associated dyskinesia and reported Phase 2 results in obese sarcopenic seniors.
Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases.
BiotechHealthtechLongevityIrvine, US
Hans Keirstead(Chairman of the Board)
Co-investorsBold Capital PartnersJLSquadraScope Venture Fund
NapaJen Pharma is a biopharmaceutical research and development company developing nucleic acid (oligonucleotide) drugs using a proprietary cell-specific drug delivery platform that enables delivery to immune cells for precision-targeted immunosuppression and controlled immuno-stimulation.
BiotechDeep TechMedical DevicesSeattle, US
有馬賢治(CEO & Director (NapaJen Pharma, Inc.); Representative Director (NapaJen Pharma K.K.))
Co-investorsRDiscovery
KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.
AI & Machine LearningBiotechDeep Tech
Co-investorsLumira Ventures
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsFast Track Initiative4BIO CapitalDCI Partners Co. Ltd.
Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
Dr. Rajendra S. Apte(Paul A. Cibis Distinguished Professor; Vice Chair of Innovation and Translation; Founder)
Co-investorsAstellas Venture Management LLCDBJ CapitalJIC Venture Growth InvestmentsKyoto University Innovation CapitalNippon Venture CapitalOSAKA University Venture Capital+3 more
Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease.
BiotechDeep TechHealthtechSan Francisco Bay Area, US
Titus Plattel(Leadership Team)inBrian Rogers(Leadership Team)inNeil Schwartz(Leadership Team)inSujata Sankar(Leadership Team)inSteven King(Leadership Team)in
Co-investorsKyoto University Innovation CapitalMiyako CapitalRDiscovery
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.